Which has higher valuation and earnings, EWTX or BCAX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Bicara Therapeutics N/A N/A -$137.95M -$3.10 N/A

Is EWTX or BCAX more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat Bicara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Bicara Therapeutics N/A -41.49% -38.59%

Does the media refer more to EWTX or BCAX?

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.34 beat Edgewise Therapeutics' score of 0.07 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BCAX or RLAY more profitable?

Bicara Therapeutics' return on equity of -41.49% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bicara Therapeutics N/A -41.49% -38.59% Relay Therapeutics N/A -42.27% -38.67%

Does the media prefer BCAX or RLAY?

In the previous week, Relay Therapeutics had 7 more articles in the media than Bicara Therapeutics. MarketBeat recorded 11 mentions for Relay Therapeutics and 4 mentions for Bicara Therapeutics. Relay Therapeutics' average media sentiment score of 0.44 beat Bicara Therapeutics' score of 0.34 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relay Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ABCL or BCAX?

In the previous week, AbCellera Biologics had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 5 mentions for AbCellera Biologics and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.34 beat AbCellera Biologics' score of 0.00 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TNGX or BCAX more profitable?

Tango Therapeutics' return on equity of -25.75% beat Bicara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -25.75% -23.36% Bicara Therapeutics N/A -41.49% -38.59%

Does the media favor TNGX or BCAX?

In the previous week, Tango Therapeutics had 3 more articles in the media than Bicara Therapeutics. MarketBeat recorded 7 mentions for Tango Therapeutics and 4 mentions for Bicara Therapeutics. Tango Therapeutics' average media sentiment score of 0.79 beat Bicara Therapeutics' score of 0.34 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BCAX or VCYT?

In the previous week, Bicara Therapeutics and Bicara Therapeutics both had 4 articles in the media. Veracyte's average media sentiment score of 0.37 beat Bicara Therapeutics' score of 0.34 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veracyte 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bicara Therapeutics (BCAX) Competitors

$17.50 +0.24 (+1.39%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$17.51 +0.01 (+0.06%)

As of 10/9/2026 07:30 PM Eastern

Compare

BCAX vs. EWTX, RLAY, ABCL, TNGX, and VCYT

Should you buy Bicara Therapeutics stock or one of its competitors? Bicara Therapeutics's main competitors and comparable companies include Edgewise Therapeutics (EWTX), Relay Therapeutics (RLAY), AbCellera Biologics (ABCL), Tango Therapeutics (TNGX), and Veracyte (VCYT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Bicara Therapeutics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Bicara Therapeutics (NASDAQ:BCAX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Edgewise Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.7, indicating that its stock price is 170% less volatile than the broader market.

Edgewise Therapeutics currently has a consensus target price of $51.33, indicating a potential upside of 31.42%. Bicara Therapeutics has a consensus target price of $32.64, indicating a potential upside of 86.49%. Given Bicara Therapeutics' higher possible upside, analysts clearly believe Bicara Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Bicara Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.75

Edgewise Therapeutics' return on equity of -39.01% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.34 beat Edgewise Therapeutics' score of 0.07 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Edgewise Therapeutics and Bicara Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Bicara Therapeutics compare to Relay Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

In the previous week, Relay Therapeutics had 7 more articles in the media than Bicara Therapeutics. MarketBeat recorded 11 mentions for Relay Therapeutics and 4 mentions for Bicara Therapeutics. Relay Therapeutics' average media sentiment score of 0.44 beat Bicara Therapeutics' score of 0.34 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relay Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bicara Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A
Relay Therapeutics	$15.35M	255.26	-$276.48M	-$1.57	N/A

Bicara Therapeutics has a beta of -0.7, suggesting that its share price is 170% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market.

Bicara Therapeutics' return on equity of -41.49% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-41.49%	-38.59%
Relay Therapeutics	N/A	-42.27%	-38.67%

Bicara Therapeutics currently has a consensus target price of $32.64, indicating a potential upside of 86.49%. Relay Therapeutics has a consensus target price of $25.92, indicating a potential upside of 44.95%. Given Bicara Therapeutics' higher possible upside, analysts clearly believe Bicara Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.75
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

97.0% of Relay Therapeutics shares are owned by institutional investors. 13.8% of Bicara Therapeutics shares are owned by insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Relay Therapeutics beats Bicara Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Bicara Therapeutics (NASDAQ:BCAX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

AbCellera Biologics has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.7, meaning that its stock price is 170% less volatile than the broader market.

In the previous week, AbCellera Biologics had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 5 mentions for AbCellera Biologics and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.34 beat AbCellera Biologics' score of 0.00 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AbCellera Biologics presently has a consensus price target of $13.38, indicating a potential upside of 6.57%. Bicara Therapeutics has a consensus price target of $32.64, indicating a potential upside of 86.49%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Bicara Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.75

Bicara Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Bicara Therapeutics	N/A	-41.49%	-38.59%

61.4% of AbCellera Biologics shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bicara Therapeutics has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	51.22	-$146.41M	-$0.54	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

Summary

AbCellera Biologics and Bicara Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Bicara Therapeutics compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Bicara Therapeutics (NASDAQ:BCAX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Tango Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.7, suggesting that its stock price is 170% less volatile than the broader market.

Tango Therapeutics has higher revenue and earnings than Bicara Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$53.81M	74.61	-$101.59M	-$0.85	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

In the previous week, Tango Therapeutics had 3 more articles in the media than Bicara Therapeutics. MarketBeat recorded 7 mentions for Tango Therapeutics and 4 mentions for Bicara Therapeutics. Tango Therapeutics' average media sentiment score of 0.79 beat Bicara Therapeutics' score of 0.34 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.0% of Tango Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tango Therapeutics' return on equity of -25.75% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Tango Therapeutics currently has a consensus price target of $43.46, indicating a potential upside of 82.53%. Bicara Therapeutics has a consensus price target of $32.64, indicating a potential upside of 86.49%. Given Bicara Therapeutics' higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Bicara Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.75

Summary

Tango Therapeutics beats Bicara Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to Veracyte?

Bicara Therapeutics (NASDAQ:BCAX) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Veracyte has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A
Veracyte	$517.15M	7.03	$66.35M	$1.41	32.08

Bicara Therapeutics currently has a consensus target price of $32.64, indicating a potential upside of 86.49%. Veracyte has a consensus target price of $55.78, indicating a potential upside of 23.32%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Bicara Therapeutics is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.75
Veracyte	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Veracyte has a net margin of 20.37% compared to Bicara Therapeutics' net margin of 0.00%. Veracyte's return on equity of 9.26% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-41.49%	-38.59%
Veracyte	20.37%	9.26%	8.61%

In the previous week, Bicara Therapeutics and Bicara Therapeutics both had 4 articles in the media. Veracyte's average media sentiment score of 0.37 beat Bicara Therapeutics' score of 0.34 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veracyte	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bicara Therapeutics has a beta of -0.7, meaning that its share price is 170% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market.

Summary

Veracyte beats Bicara Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Bicara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAX vs. The Competition

Export

Metric	Bicara Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.14B	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.36%
P/E Ratio	-5.65	13.42	274.13	26.16
Price / Sales	N/A	1,240.95	590.44	94.78
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	2.39	17.17	11.21	6.34
Net Income	-$137.95M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-0.74%	-1.33%	-0.92%	-1.41%
1 Month Performance	-24.24%	-8.44%	-4.46%	-3.48%
1 Year Performance	-1.57%	14.02%	6.94%	1.16%

Bicara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAX Bicara Therapeutics	2.5902 of 5 stars	$17.50 +1.4%	$32.64 +86.5%	-4.2%	$1.14B	N/A	N/A	103
EWTX Edgewise Therapeutics	2.8346 of 5 stars	$40.02 -0.7%	$51.33 +28.3%	+143.4%	$4.38B	N/A	N/A	127	News Coverage
RLAY Relay Therapeutics	2.5199 of 5 stars	$18.74 -3.4%	$25.92 +38.3%	+163.7%	$4.25B	$15.35M	N/A	192	Trending News Insider Trade Gap Down
ABCL AbCellera Biologics	1.2562 of 5 stars	$13.15 -4.6%	$13.38 +1.7%	+112.4%	$4.23B	$75.13M	N/A	562
TNGX Tango Therapeutics	2.6958 of 5 stars	$21.90 -5.1%	$43.46 +98.5%	+225.3%	$3.89B	$53.81M	N/A	137

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicara Therapeutics (BCAX) Competitors

BCAX vs. EWTX, RLAY, ABCL, TNGX, and VCYT

How does Bicara Therapeutics compare to Edgewise Therapeutics?

Summary

How does Bicara Therapeutics compare to Relay Therapeutics?

Summary

How does Bicara Therapeutics compare to AbCellera Biologics?

Summary

How does Bicara Therapeutics compare to Tango Therapeutics?

Summary

How does Bicara Therapeutics compare to Veracyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicara Therapeutics (BCAX) Competitors

BCAX vs. EWTX, RLAY, ABCL, TNGX, and VCYT

How does Bicara Therapeutics compare to Edgewise Therapeutics?

Which has more risk and volatility, EWTX or BCAX?

Do analysts rate EWTX or BCAX?

Is EWTX or BCAX more profitable?

Which has higher valuation and earnings, EWTX or BCAX?

Does the media refer more to EWTX or BCAX?

Summary

How does Bicara Therapeutics compare to Relay Therapeutics?

Does the media prefer BCAX or RLAY?

Which has better valuation and earnings, BCAX or RLAY?

Which has more risk and volatility, BCAX or RLAY?

Is BCAX or RLAY more profitable?

Do analysts rate BCAX or RLAY?

Do insiders & institutionals believe in BCAX or RLAY?

Summary

How does Bicara Therapeutics compare to AbCellera Biologics?

Which has more volatility & risk, ABCL or BCAX?

Does the media refer more to ABCL or BCAX?

Do analysts prefer ABCL or BCAX?

Is ABCL or BCAX more profitable?

Do insiders and institutionals believe in ABCL or BCAX?

Which has better earnings and valuation, ABCL or BCAX?

Summary

How does Bicara Therapeutics compare to Tango Therapeutics?

Which has more risk & volatility, TNGX or BCAX?

Which has better valuation & earnings, TNGX or BCAX?

Does the media favor TNGX or BCAX?

Do institutionals and insiders have more ownership in TNGX or BCAX?

Is TNGX or BCAX more profitable?

Do analysts prefer TNGX or BCAX?

Summary

How does Bicara Therapeutics compare to Veracyte?

Which has better earnings & valuation, BCAX or VCYT?

Do analysts recommend BCAX or VCYT?

Is BCAX or VCYT more profitable?

Does the media favor BCAX or VCYT?

Which has more risk and volatility, BCAX or VCYT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools